• Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

    ソース: Nasdaq GlobeNewswire / 03 1 2024 05:30:00   America/Chicago

    N/A
シェアする